392 related articles for article (PubMed ID: 25329562)
1. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.
Walters JR; Johnston IM; Nolan JD; Vassie C; Pruzanski ME; Shapiro DA
Aliment Pharmacol Ther; 2015 Jan; 41(1):54-64. PubMed ID: 25329562
[TBL] [Abstract][Full Text] [Related]
2. Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
Al-Dury S; Wahlström A; Panzitt K; Thorell A; Ståhlman M; Trauner M; Fickert P; Bäckhed F; Fändriks L; Wagner M; Marschall HU
J Hepatol; 2019 Nov; 71(5):986-991. PubMed ID: 31254596
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention.
Pattni SS; Brydon WG; Dew T; Johnston IM; Nolan JD; Srinivas M; Basumani P; Bardhan KD; Walters JR
Aliment Pharmacol Ther; 2013 Oct; 38(8):967-76. PubMed ID: 23981126
[TBL] [Abstract][Full Text] [Related]
4. Obeticholic acid for severe bile acid diarrhea with intestinal failure: A case report and review of the literature.
Hvas CL; Ott P; Paine P; Lal S; Jørgensen SP; Dahlerup JF
World J Gastroenterol; 2018 Jun; 24(21):2320-2326. PubMed ID: 29881241
[TBL] [Abstract][Full Text] [Related]
5. Characterizing Factors Associated With Differences in FGF19 Blood Levels and Synthesis in Patients With Primary Bile Acid Diarrhea.
Johnston IM; Nolan JD; Pattni SS; Appleby RN; Zhang JH; Kennie SL; Madhan GK; Jameie-Oskooei S; Pathmasrirengam S; Lin J; Hong A; Dixon PH; Williamson C; Walters JR
Am J Gastroenterol; 2016 Mar; 111(3):423-32. PubMed ID: 26856750
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study.
Appleby RN; Moghul I; Khan S; Yee M; Manousou P; Neal TD; Walters JRF
PLoS One; 2019; 14(1):e0211348. PubMed ID: 30682184
[TBL] [Abstract][Full Text] [Related]
7. Chenodeoxycholic acid stimulated fibroblast growth factor 19 response - a potential biochemical test for bile acid diarrhoea.
Borup C; Wildt S; Rumessen JJ; Bouchelouche PN; Graff J; Damgaard M; McQuitty C; Rainteau D; Munck LK
Aliment Pharmacol Ther; 2017 Jun; 45(11):1433-1442. PubMed ID: 28378364
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea.
Camilleri M; Nord SL; Burton D; Oduyebo I; Zhang Y; Chen J; Im K; Bhad P; Badman MK; Sanders DS; Walters JRF
Aliment Pharmacol Ther; 2020 Sep; 52(5):808-820. PubMed ID: 32702169
[TBL] [Abstract][Full Text] [Related]
9. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids.
Zhang JH; Nolan JD; Kennie SL; Johnston IM; Dew T; Dixon PH; Williamson C; Walters JR
Am J Physiol Gastrointest Liver Physiol; 2013 May; 304(10):G940-8. PubMed ID: 23518683
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
11. Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy.
Walters JR
Nat Rev Gastroenterol Hepatol; 2014 Jul; 11(7):426-34. PubMed ID: 24662279
[TBL] [Abstract][Full Text] [Related]
12. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
Ho PP; Steinman L
Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456
[TBL] [Abstract][Full Text] [Related]
13. Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge.
Zweers SJ; de Vries EM; Lenicek M; Tolenaars D; de Waart DR; Koelfat KV; Groen AK; Olde Damink SW; Beuers U; Ponsioen C; Jansen PL; Schaap FG
Hepatol Int; 2017 Jan; 11(1):132-140. PubMed ID: 27696157
[TBL] [Abstract][Full Text] [Related]
14. An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers.
Al-Khaifi A; Rudling M; Angelin B
Gastroenterology; 2018 Oct; 155(4):1012-1016. PubMed ID: 29928896
[TBL] [Abstract][Full Text] [Related]
15. The role of bile acids in functional GI disorders.
Appleby RN; Walters JR
Neurogastroenterol Motil; 2014 Aug; 26(8):1057-69. PubMed ID: 24898156
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of Serum and Distal Ileum Fibroblast Growth Factor19 in Bile Acid Diarrhoea Patients.
Chang C; Jiang J; Sun R; Wang S; Chen H
Dig Dis Sci; 2022 Mar; 67(3):872-879. PubMed ID: 34041651
[TBL] [Abstract][Full Text] [Related]
17. Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease.
Battat R; Duijvestein M; Vande Casteele N; Singh S; Dulai PS; Valasek MA; Mimms L; McFarland J; Hester KD; Renshaw M; Jain A; Sandborn WJ; Boland BS
Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2722-2730.e4. PubMed ID: 30448597
[TBL] [Abstract][Full Text] [Related]
18. Performance characteristics of serum C4 and FGF19 measurements to exclude the diagnosis of bile acid diarrhoea in IBS-diarrhoea and functional diarrhoea.
Vijayvargiya P; Camilleri M; Carlson P; Lueke A; O'Neill J; Burton D; Busciglio I; Donato L
Aliment Pharmacol Ther; 2017 Sep; 46(6):581-588. PubMed ID: 28691284
[TBL] [Abstract][Full Text] [Related]
19. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis.
Walters JR; Tasleem AM; Omer OS; Brydon WG; Dew T; le Roux CW
Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1189-94. PubMed ID: 19426836
[TBL] [Abstract][Full Text] [Related]
20. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial.
Friedrich D; Marschall HU; Lammert F
BMC Gastroenterol; 2018 Jun; 18(1):76. PubMed ID: 29866129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
